Results - location/NSW/2145-Westmead-The-Children-s-Hospital-at-Westmead - ARTICANZ

ARTICANZ - Beta (ver 0.91)

Annotated Registry of Trials in Cancer, Australia and New Zealand Ed. - Results - location/NSW/2145-Westmead-The-Children-s-Hospital-at-Westmead

Search results

19 trial(s) found.

Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer (OPTIMISE)

CAMPFIRE: Children's and Young Adult Master Protocol for Innovative Pediatric Research

A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma (Glo-BNHL)

A Feasibility and Randomized Phase 2/3 Study of the VEGFR2/MET Inhibitor Cabozantinib in Combination With Cytotoxic Chemotherapy for Newly Diagnosed Osteosarcoma (NCI-2022-08567)

2031 - Randwick - Sydney Children's Hospital (SUSPENDED)

LOGGIC/FIREFLY-2: A Phase 3, Randomized, International Multicenter Trial of DAY101 Monotherapy Versus Standard of Care Chemotherapy in Patients With Pediatric Low-Grade Glioma Harboring an Activating RAF Alteration Requiring First-Line Systemic Therapy (DAY101-002)

Interfant-21 International Collaborative Treatment Protocol for Infants Under One Year With KMT2A-rearranged Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia.

NA

8011 - Christchurch - Christchurch Children's Hospital

A Prospective Phase 3 Study of Patients With Newly Diagnosed Very Low-Risk and Low-Risk Fusion Negative Rhabdomyosarcoma (ARST2032)

Phase III Randomized Double-blind Placebo-controlled Trial of Metformin for Cognitive Recovery and White Matter Growth in Paediatric Patients With a Brain Tumour (Met-Med-Can)

2145 - Westmead - The Children's Hospital at Westmead (WITHDRAWN)

A Phase 1/2 Trial of Selinexor (KPT-330) and Radiation Therapy in Newly-Diagnosed Pediatric Diffuse Intrinsic Pontine Glioma (DIPG) and High-Grade Glioma (HGG) (NCI-2021-11337)

Targeted Therapy to Increase RAI Uptake in Patients With Metastatic Differentiated Thyroid Cancer (21-018612)

FIREFLY-1: A Phase 2, Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of the Oral Pan-RAF Inhibitor DAY101 in Pediatric Patients With RAF-Altered, Recurrent or Progressive Low-Grade Glioma and Advanced Solid Tumors

A Phase 2 Trial of Chemotherapy Followed by Response-Based Whole Ventricular &Amp; Spinal Canal Irradiation (WVSCI) for Patients With Localized Non-Germinomatous Central Nervous System Germ Cell Tumor (ACNS2021)

FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma

A Single Arm, Pilot of Neoadjuvant Checkpoint Inhibition Followed by Adjuvant Checkpoint Inhibition in Children and Young Adults With Recurrent or Progressive High Grade Glioma (HGG)

A Phase 3 Randomized Trial for Patients With De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 With GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients With FLT3 Mutations (AAML1831)

High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN) (HR-NBL2)

2145 - Westmead - The Children's Hospital at Westmead (SUSPENDED)

WA6009 - Perth - Perth Children's Hospital (SUSPENDED)

A Phase 1/2, Open-Label, Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity Study of Repotrectinib in Pediatric and Young Adult Subjects With Advanced or Metastatic Malignancies Harboring ALK, ROS1, NTRK1-3 Alterations (CA127-1029)

2145 - Westmead - The Children's Hospital at Westmead (COMPLETED)

INFORM2 Exploratory Multinational Phase I/II Combination Study of Nivolumab and Entinostat in Children and Adolescents With Refractory High-risk Malignancies (INFORM2-NivEnt) (Final4,-18-10-2023)

International Randomised Phase III Clinical Trial in Children With Acute Myeloid Leukaemia - Incorporating an Embedded Dose Finding Study for Gemtuzumab Ozogamicin in Combination With Induction Chemotherapy (Myechild01)

Filters

Recruitment Status

Recruitment Country and State

Phase

Trial Type

Cancer Therapy Class

PD-1	16%
PD-1/PD-L1	16%
VEGFR2	11%
CD19	11%
AXL	11%
KIT	11%
RET	11%
ROS1	11%
VEGFR	11%
BRAF	11%
CRAF	11%
RAF	11%
pan-RAF	11%
CD33	11%
LAG3	5%
PI3K	5%
PI3K delta	5%
PI3Kalpha	5%
mTOR	5%
mTORC1	5%
mTORC2	5%
CDK4	5%
CDK6	5%
CD20	5%
MET	5%
XPO1	5%
FGFR1	5%
FGFR1/2/3	5%
FGFR2	5%
FGFR3	5%
FGFR4	5%
PDGFR	5%
FLT3	5%
GD2	5%
ALK	5%
TRK	5%
HDAC	5%

Facility

Cancer Type

ARTICANZ (Annotated Registry of Trials in Cancer, Australia/NZ Edition; ARTificial Intelligence-enhanced CANcer trial information database) provides information about cancer drug trials in Australia and New Zealand as a free, open-information platform. Please note the following:

Data Accuracy: While ARTICANZ strives to maintain accurate and up-to-date information through regular weekly updates and specialist review, we cannot guarantee the complete accuracy, reliability, or timeliness of all data. Information may change between updates.
Not Medical Advice: The information provided by ARTICANZ is for informational purposes only and should not be considered medical advice. All clinical decisions should be made in consultation with qualified healthcare professionals.
No Warranty: ARTICANZ is provided "as is" without any warranties, expressed or implied. We disclaim all liability for any damages arising from the use of or inability to use this platform.
External Links: ARTICANZ may contain links to external websites. We are not responsible for the content or privacy practices of these sites.

By using ARTICANZ, you acknowledge that you have read and understood this disclaimer.

The ARTICANZ platform and its contents are made available under the Creative Commons Attribution 4.0 International License (CC BY 4.0).

Users are free to:

Share — copy and redistribute the data in any medium or format
Adapt — remix, transform, and build upon the data
Use the data for any purpose, including commercial use

Under the following terms:

Attribution — You must give appropriate credit to ARTICANZ, provide a link to the license, and indicate if changes were made
No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits

Platform developed and currently maintained by Dr. Frank Lin and the ARTICANZ team.